Spero Therapeutics, Inc. (SPRO)
1.20
-0.02
(-1.64%)
USD |
NASDAQ |
Sep 01, 12:59
Spero Therapeutics Cash from Operations (TTM) : 19.58M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 19.58M |
| March 31, 2026 | 7.242M |
| December 31, 2025 | -12.62M |
| September 30, 2025 | -27.67M |
| June 30, 2025 | -32.33M |
| March 31, 2025 | -33.38M |
| December 31, 2024 | -23.44M |
| September 30, 2024 | -17.54M |
| June 30, 2024 | -14.38M |
| March 31, 2024 | -14.20M |
| December 31, 2023 | -33.00M |
| September 30, 2023 | 28.98M |
| June 30, 2023 | 12.11M |
| March 31, 2023 | 7.639M |
| December 31, 2022 | -7.731M |
| September 30, 2022 | -79.56M |
| Date | Value |
|---|---|
| June 30, 2022 | -83.56M |
| March 31, 2022 | -77.09M |
| December 31, 2021 | -64.35M |
| September 30, 2021 | -53.38M |
| June 30, 2021 | -69.69M |
| March 31, 2021 | -78.02M |
| December 31, 2020 | -85.87M |
| September 30, 2020 | -86.86M |
| June 30, 2020 | -75.25M |
| March 31, 2020 | -62.42M |
| December 31, 2019 | -50.02M |
| September 30, 2019 | -46.16M |
| June 30, 2019 | -42.02M |
| March 31, 2019 | -38.59M |
| December 31, 2018 | -39.62M |
| September 30, 2018 | -38.86M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Inovio Pharmaceuticals, Inc. | -80.58M |
| Fortress Biotech, Inc. | 120.36M |
| Kura Oncology, Inc. | -111.76M |
| Legend Biotech Corp. | -182.95M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |